Peripheral T-cell lymphoma (PTCL) consists of a group of rare and usually aggressive non-Hodgkin lymphomas (NHLs) that develop from mature T-cells.

There are 27 subtypes of PTCL (WHO, 2016), of which the most common 6 subtypes account for >75% of cases. These include PTCL-NOS, anaplastic lymphoma kinase (ALK+/ALK-) anaplastic large cell lymphoma (ALCL), angioimmunoblastic T-cell lymphoma (AITL), NK/T-cell lymphoma, and adult T-cell leukemia/lymphoma (ATLL).

The CHOP-based chemotherapy regimen has remained the standard of treatment for most PTCLs in recent years; however, newer treatments are now available for PTCL, including antibody-drug conjugates such as brentuximab vedotin, and ALK inhibitors are promising for ALK expressing tumors. The use of checkpoint inhibitors remains controversial.

View Aggressive T-Cell & NK-Cell Lymphoma Overview Page

Peripheral T-Cell Lymphoma

The Lymphoma Channel on VJHemOnc is supported by Takeda and Karyopharm Therapeutics. The companies have no influence over the production of the content.

Peripheral T-Cell Lymphoma

Peripheral T-cell lymphoma (PTCL) consists of a group of rare and usually aggressive non-Hodgkin lymphomas (NHLs) that develop from mature T-cells.

There are 27 subtypes of PTCL (WHO, 2016), of which the most common 6 subtypes account for >75% of cases. These include PTCL-NOS, anaplastic lymphoma kinase (ALK+/ALK-) anaplastic large cell lymphoma (ALCL), angioimmunoblastic T-cell lymphoma (AITL), NK/T-cell lymphoma, and adult T-cell leukemia/lymphoma (ATLL).

The CHOP-based chemotherapy regimen has remained the standard of treatment for most PTCLs in recent years; however, newer treatments are now available for PTCL, including antibody-drug conjugates such as brentuximab vedotin, and ALK inhibitors are promising for ALK expressing tumors. The use of checkpoint inhibitors remains controversial.

The Lymphoma Channel on VJHemOnc is supported by Takeda and Karyopharm Therapeutics. The companies have no influence over the production of the content.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter